Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis


Blatt, K (2015) Blood (Link to abstract)



Brentuximab vedotin (BV), a chimeric antibody linked to an anti-tubulin agent targets CD-30 or Ki1 antigen. BV has been used in Hodgkin lymphoma and anaplastic large-cell lymphoma (ALCL) in refractory/ relapsed patients with some success. This article shows that CD30 is expressed in about 50% of patients with aggressive systemic mastocytosis or mastocytic leukemia but only in 12% with indolent disease. The authors showed that BV inhibits CD30 expressing cells in vitro and in vivo mouse engraftment models. The effect of BV was enhanced when given with a drug (PKC412) targeting the most common gene mutation in mastocytosis KIT D816V.


* This study suggests that Brentuximab vedotin might be used in systemic mastocytosis with advanced disease.